{"id":3299,"date":"2022-03-15T14:17:00","date_gmt":"2022-03-15T14:17:00","guid":{"rendered":"https:\/\/www.kestersearch.com\/insights-and-events\/?p=3299"},"modified":"2022-03-15T02:22:19","modified_gmt":"2022-03-15T02:22:19","slug":"saol-therapeutics-genedx-partner-to-id-patients-with-rare-mitochondrial-disease","status":"publish","type":"post","link":"https:\/\/www.kestersearch.com\/insights-and-events\/news\/2022\/03\/saol-therapeutics-genedx-partner-to-id-patients-with-rare-mitochondrial-disease\/","title":{"rendered":"Saol Therapeutics, GeneDx Partner to ID Patients With Rare Mitochondrial Disease"},"content":{"rendered":"\n<p>Saol Therapeutics and GeneDx have partnered to identify patients with rare mitochondrial disease. There are currently no FDA-approved treatments for patients with PDCD so this is a huge step in the right <a href=\"direction:\" title=\"https:\/\/www.genomeweb.com\/molecular-diagnostics\/saol-therapeutics-genedx-partner-id-patients-rare-mitochondrial-disease?utm_campaign=GenomeWeb+Welcome+Email&amp;utm_medium=email&amp;CSAuthResp=1646709212012%3A0%3A2509390%3A0%3A24%3Asuccess%3A03ECD52A0F403DF0F653EA3E7381BBF1&amp;_ga=2.228562205.1018813346.1646708800-392805638.1646708800&amp;adobe_mc=MCMID%3D58249170293482126101269122116831728199%7CMCORGID%3D138FFF2554E6E7220A4C98C6%2540AdobeOrg%7CTS%3D1646709060&amp;utm_source=Sailthru&amp;CSAuthReq=1#.YibJ6nrMK5c\">direction:<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Saol Therapeutics and GeneDx have partnered to identify patients with rare mitochondrial disease. There are currently no FDA-approved treatments for patients with PDCD so this is a huge step in the right direction:<\/p>\n","protected":false},"author":13,"featured_media":3301,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[2],"tags":[123,107,25,377],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.kestersearch.com\/insights-and-events\/wp-json\/wp\/v2\/posts\/3299"}],"collection":[{"href":"https:\/\/www.kestersearch.com\/insights-and-events\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.kestersearch.com\/insights-and-events\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.kestersearch.com\/insights-and-events\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.kestersearch.com\/insights-and-events\/wp-json\/wp\/v2\/comments?post=3299"}],"version-history":[{"count":1,"href":"https:\/\/www.kestersearch.com\/insights-and-events\/wp-json\/wp\/v2\/posts\/3299\/revisions"}],"predecessor-version":[{"id":3302,"href":"https:\/\/www.kestersearch.com\/insights-and-events\/wp-json\/wp\/v2\/posts\/3299\/revisions\/3302"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.kestersearch.com\/insights-and-events\/wp-json\/wp\/v2\/media\/3301"}],"wp:attachment":[{"href":"https:\/\/www.kestersearch.com\/insights-and-events\/wp-json\/wp\/v2\/media?parent=3299"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.kestersearch.com\/insights-and-events\/wp-json\/wp\/v2\/categories?post=3299"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.kestersearch.com\/insights-and-events\/wp-json\/wp\/v2\/tags?post=3299"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}